Dan Peer is a Professor and Director of the Laboratory of Precision Nanomedicine at Tel Aviv University (TAU). From 2020 he also acts as Vice President for Research & Development at TAU. Dan gained his entire training at Tel Aviv University with internships at the University of Cambridge, UK, at MIT, and a postdoctoral fellowship at Harvard Medical School.

In 2008 he returned to Tel Aviv University to establish the Laboratory of Precision Nanomedicine. Dan pioneered the field of Active Cellular Targeting (ACT) to deliver RNA payloads in a cell specific manner. He developed one of the largest lipid libraries in the world with more than 100,000 different lipids. His lab was the first to show systemic, cell specific delivery of small interfering (si)RNAs to immune cells.

Also, the first to show systemic, cell specific delivery of messenger (m)RNA that expresses a therapeutic protein in an animal model, and the first to show highly efficient therapeutic genome editing in cancer, also in a cell type specific manner.

He also developed the first successful bacterial mRNA vaccine. He is the recipient of more than 40 awards and honors. He holds 150 pending and granted patents, 60% of which are licensed to companies. In addition, more than 10 strategies he developed are currently under clinical trials including novel RNA modality (the first circular (circ)RNA in the clinic).

He is also the founder of 4 startup companies (one was acquired in 2021). Dan was elected to the Israel Young Academy in 2014 (and served as co-chairman of the Academy until the end of 2015). He was elected International Member of the US National Academy of Engineering in 2023; elected as a Fellow of the US National Academy of Inventors in 2024, and as a Fellow of the Controlled Release Society in 2025.